Multimodal treatment for resectable esophageal cancer
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Hiroshi Miyata, MD · Makoto Yamasaki, MD Yukinori Kurokawa, MD · Shuji Takiguchi, MD Kiyokazu Nakajima, MD · Yoshiyuki Fujiwara, MD Masaki Mori, MD
- چاپ و سال / کشور: 2011
Description
Surgical resection has been traditionally the mainstay of treatment for localized esophageal cancers. However, survival after surgery alone for advanced esophageal cancer is not satisfactory. In Japan, the development of multimodal therapy for esophageal cancers has centered mainly on systemic chemotherapy plus surgery to control distant metastasis. Based on the results of the recent Japan Clinical Oncology Group (JCOG) 9907 study, preoperative chemotherapy (consisting of 5-FU and cisplatin) followed by surgery has emerged as the standard treatment. In Western countries, where chemoradiotherapy followed by surgery has been mainly explored for patients with resectable esophageal cancers, two large controlled trials that evaluated the effectiveness of preoperative chemotherapy reported confl icting results. However, a recent meta-analysis reported signifi cant survival benefi ts for preoperative chemotherapy in patients with adenocarcinoma of the esophagus. We need to fi nd new effective preoperative chemotherapeutic regimens, including molecular target agents, with response rates higher than that of the conventional chemotherapy of 5-FU and cisplatin. However, we also must compare the survival benefi ts of preoperative chemotherapy with preoperative chemoradiotherapy
Gen Thorac Cardiovasc Surg (2011) 59:461–466 DOI 10.1007/s11748-011-0780-6 Received: 27 October 2010 / Accepted: 7 January 2011
